U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C10H20N2S4
Molecular Weight 296.539
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DISULFIRAM

SMILES

CCN(CC)C(=S)SSC(=S)N(CC)CC

InChI

InChIKey=AUZONCFQVSMFAP-UHFFFAOYSA-N
InChI=1S/C10H20N2S4/c1-5-11(6-2)9(13)15-16-10(14)12(7-3)8-4/h5-8H2,1-4H3

HIDE SMILES / InChI

Molecular Formula C10H20N2S4
Molecular Weight 296.539
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: Description was created based on several sources, including https://www.drugs.com/pro/disulfiram.html

Disulfiram is a carbamate derivative used as an alcohol deterrent. It is a relatively nontoxic substance when administered alone, but markedly alters the intermediary metabolism of alcohol. Disulfiram blocks the oxidation of alcohol at the acetaldehyde stage during alcohol metabolism following disulfiram intake causing an accumulation of acetaldehyde in the blood producing highly unpleasant symptoms. Disulfiram blocks the oxidation of alcohol through its irreversible inactivation of aldehyde dehydrogenase, which acts in the second step of ethanol utilization. In addition, disulfiram competitively binds and inhibits the peripheral benzodiazepine receptor, which may indicate some value in the treatment of the symptoms of alcohol withdrawal, however this activity has not been extensively studied. Used for the treatment and management of chronic alcoholism.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Disulfiram

Approved Use

Disulfiram is an aid in the management of selected chronic alcohol patients who want to remain in a state of enforced sobriety so that supportive and psychotherapeutic treatment may be applied to best advantage.

Launch Date

1981
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
1.3 nM
500 mg single, oral
dose: 500 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DISULFIRAM plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
54.696 ng/mL
500 mg single, oral
dose: 500 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DISULFIRAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
715.144 ng × h/mL
500 mg single, oral
dose: 500 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DISULFIRAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
7.3 h
500 mg single, oral
dose: 500 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DISULFIRAM plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
9.82 h
500 mg single, oral
dose: 500 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DISULFIRAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG



OverviewOther

Other InhibitorOther SubstrateOther Inducer


Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no
no (co-administration study)
Comment: Results show that single-dose disulfiram does not cause clinically significant inhibition of human CYP2C9, 2C19, 2D6, and 3A4 activities in vivo
no
no (co-administration study)
Comment: Results show that single-dose disulfiram does not cause clinically significant inhibition of human CYP2C9, 2C19, 2D6, and 3A4 activities in vivo
no
no (co-administration study)
Comment: Results show that single-dose disulfiram does not cause clinically significant inhibition of human CYP2C9, 2C19, 2D6, and 3A4 activities in vivo
no
no (co-administration study)
Comment: Results show that single-dose disulfiram does not cause clinically significant inhibition of human CYP2C9, 2C19, 2D6, and 3A4 activities in vivo
yes [Ki 12.1 uM]
yes
yes (co-administration study)
Comment: Disulfiram, a selective inhibitor of human hepatic P450 2E1, prevented 80-90% of isoflurane metabolism
PubMed

PubMed

TitleDatePubMed
Manic episode with psychosis following a lower than recommended dosage regimen of disulfiram.
2008-01-01
Behavioral couples therapy for comorbid substance use disorders and combat-related posttraumatic stress disorder among male veterans: an initial evaluation.
2008-01
Adverse effects of excessive nitric oxide on cytochrome c oxidase in lenses of hereditary cataract UPL rats.
2007-12-05
Disulfiram-induced transient optic and peripheral neuropathy: a case report.
2007-12
Quantity of ethanol absorption after excessive hand disinfection using three commercially available hand rubs is minimal and below toxic levels for humans.
2007-10-11
[Acute encephalopathy secondary to treatment with disulfiram].
2007-10-06
Perturbation of retinoic acid (RA)-mediated limb development suggests a role for diminished RA signaling in the teratogenesis of ethanol.
2007-09
Hypotension and ST depression as a result of disulfiram ethanol reaction.
2007-08
Disulfiram is an inhibitor of human purified monoacylglycerol lipase, the enzyme regulating 2-arachidonoylglycerol signaling.
2007-07-23
Induction of tibial dyschondroplasia by carbamate and thiocarbamate pesticides.
2007-06
Manic episode with psychotic symptoms associated with high dose of disulfiram: a case report.
2007-04
Naltrexone and disulfiram in patients with alcohol dependence and current depression.
2007-04
Disulfiram effects on responses to intravenous cocaine administration.
2007-03-16
Pharmacological profiling of disulfiram using human tumor cell lines and human tumor cells from patients.
2007-01-01
Refractive hypotension in a patient with disulfiram-ethanol reaction.
2007-01
Bench-to-bedside review: current evidence for extracorporeal albumin dialysis systems in liver failure.
2007
[Disulfiram-induced delirium: a case report].
2006-12
Disulfiram, a clinically used anti-alcoholism drug and copper-binding agent, induces apoptotic cell death in breast cancer cultures and xenografts via inhibition of the proteasome activity.
2006-11-01
Antabuse reaction with ceftin.
2006-11
[Optic neuropathy while taking disulfiram].
2006-10
Choosing the right medication for the treatment of alcoholism.
2006-10
Involvement of drug-specific T cells in acute drug-induced interstitial nephritis.
2006-10
The catatonic dilemma expanded.
2006-09-07
[New developments in the pharmacotherapy of cocaine dependence].
2006-09
Quantification of breath carbon disulphide and acetone following a single dose of disulfiram (Antabuse) using selected ion flow tube mass spectrometry (SIFT-MS).
2006-06
[Is Antabus therapy connected with reduced efficacy of nitroglycerin?].
2006-04-24
Transgenic analysis of the medaka mesp-b enhancer in somitogenesis.
2006-04
Clinical characteristics and prognostic markers in disulfiram-induced liver injury.
2006-04
Disulfiram irreversibly aggregates betaine aldehyde dehydrogenase--a potential target for antimicrobial agents against Pseudomonas aeruginosa.
2006-03-10
Cross-reactivity between thiurams.
2006-03
Effects of dopamine beta-hydroxylase genotype and disulfiram inhibition on catecholamine homeostasis in mice.
2005-11
[The first to go--physicians who experimented on themselves].
2005-09-08
Fulminant drug-induced hepatic failure leading to death or liver transplantation in Sweden.
2005-09
Effect of inducers of DT-diaphorase on the haemolytic activity and nephrotoxicity of 2-amino-1,4-naphthoquinone in rats.
2005-08-15
Disulfiram metabolites permanently inactivate the human multidrug resistance P-glycoprotein.
2005-07-21
Are alcoholism treatments effective? The Project MATCH data.
2005-07-14
Pharmacokinetics, safety, and tolerability of a depot formulation of naltrexone in alcoholics: an open-label trial.
2005-04-01
Acute liver failure: a message found under the skin.
2005-04
Cutaneous metabolism of glycol ethers.
2005-03
Resistance of zwitterionic telomers accumulated on metal surfaces against nonspecific adsorption of proteins.
2005-02-15
Clioquinol and pyrrolidine dithiocarbamate complex with copper to form proteasome inhibitors and apoptosis inducers in human breast cancer cells.
2005
[Anterior myocardial infarction in a chronic alcoholic man on disulfiram therapy: a case report].
2004-12
One-pot synthesis of high-quality zinc-blende CdS nanocrystals.
2004-11-10
Preparation of mononuclear and dinuclear Rh hydrotris(pyrazolyl)borato complexes containing arenethiolato ligands and conversion of the mononuclear complexes into dinuclear Rh-Rh and Rh-Ir complexes with bridging arenethiolato ligands.
2004-11-07
Ask the doctor. I need to quit drinking, but don't think I can do it on my own. Can I use a drug like Antabuse even though I have heart disease?
2004-10
Disulfiram is a potent modulator of multidrug transporter Cdr1p of Candida albicans.
2004-09-17
Disulfiram inhibits activating transcription factor/cyclic AMP-responsive element binding protein and human melanoma growth in a metal-dependent manner in vitro, in mice and in a patient with metastatic disease.
2004-09
Disulfiram-induced fulminant hepatic failure in an active duty soldier.
2004-08
Effectiveness of some means using against root rot on parsley seedling root.
2004
Role of human cytochrome P-450 IIE1 in the oxidation of many low molecular weight cancer suspects.
1991-03-01
Patents

Sample Use Guides

Usual Adult Dose for Alcohol Dependence -Initial dose: 500 mg orally once a day (this dose is generally continued for the first 1 to 2 weeks) -Maintenance dose: 250 mg orally once a day (range: 125 mg to 500 mg once a day) Maximum dose: 500 mg once a day -Duration of therapy: Depending on the individual, therapy may last months or even years
Route of Administration: Oral
Application of 1mM disulfiram to R. jostii RHA1, gave rise to 4-carboxymuconolactone on the β-ketoadipate pathway
Substance Class Chemical
Created
by admin
on Mon Mar 31 17:35:03 GMT 2025
Edited
by admin
on Mon Mar 31 17:35:03 GMT 2025
Record UNII
TR3MLJ1UAI
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
TETRAETHYLTHIOPEROXYDICARBONIC DIAMIDE ((((C(SUB 2)H(SUB 5))(SUB 2)N)C(S))(SUB 2)S(SUB 2))
Preferred Name English
DISULFIRAM
EP   HSDB   INN   MART.   MI   ORANGE BOOK   USP   USP-RS   VANDF   WHO-DD  
INN  
Official Name English
ORA102
Code English
ANTABUSE
Brand Name English
DISULFIRAM [HSDB]
Common Name English
THIOPEROXYDICARBONIC DIAMIDE ((H2N)C(S))(SUB 2) S(SUB 2), TETRAETHYL-
Common Name English
DISULFIRAM [MART.]
Common Name English
DISULFIRAM [MI]
Common Name English
Disulfiram [WHO-DD]
Common Name English
ORA-102
Code English
NSC-25953
Code English
DISULFIRAM [JAN]
Common Name English
disulfiram [INN]
Common Name English
TETRAETHYLTHIURAM DISULPHIDE
Systematic Name English
DISULFIRAM [EP IMPURITY]
Common Name English
DISULFIRAM [VANDF]
Common Name English
BIS(DIETHYLTHIOCARBAMOYL) DISULPHIDE
Systematic Name English
TETRAETHYLTHIURAM DISULFIDE
Systematic Name English
DISULFIRAM [ORANGE BOOK]
Common Name English
DISULFIRAM [IARC]
Common Name English
DISULFIRAM [USP MONOGRAPH]
Common Name English
Bis(diethylthiocarbamoyl) disulfide
Systematic Name English
DISULFIRAM [EP MONOGRAPH]
Common Name English
Classification Tree Code System Code
WHO-VATC QN07BB01
Created by admin on Mon Mar 31 17:35:03 GMT 2025 , Edited by admin on Mon Mar 31 17:35:03 GMT 2025
WHO-ATC P03AA04
Created by admin on Mon Mar 31 17:35:03 GMT 2025 , Edited by admin on Mon Mar 31 17:35:03 GMT 2025
FDA ORPHAN DRUG 522516
Created by admin on Mon Mar 31 17:35:03 GMT 2025 , Edited by admin on Mon Mar 31 17:35:03 GMT 2025
WHO-ATC N07BB01
Created by admin on Mon Mar 31 17:35:03 GMT 2025 , Edited by admin on Mon Mar 31 17:35:03 GMT 2025
NCI_THESAURUS C2160
Created by admin on Mon Mar 31 17:35:03 GMT 2025 , Edited by admin on Mon Mar 31 17:35:03 GMT 2025
LIVERTOX NBK548103
Created by admin on Mon Mar 31 17:35:03 GMT 2025 , Edited by admin on Mon Mar 31 17:35:03 GMT 2025
NDF-RT N0000175679
Created by admin on Mon Mar 31 17:35:03 GMT 2025 , Edited by admin on Mon Mar 31 17:35:03 GMT 2025
NCI_THESAURUS C1744
Created by admin on Mon Mar 31 17:35:03 GMT 2025 , Edited by admin on Mon Mar 31 17:35:03 GMT 2025
WHO-ATC P03AA54
Created by admin on Mon Mar 31 17:35:03 GMT 2025 , Edited by admin on Mon Mar 31 17:35:03 GMT 2025
NDF-RT N0000000183
Created by admin on Mon Mar 31 17:35:03 GMT 2025 , Edited by admin on Mon Mar 31 17:35:03 GMT 2025
FDA ORPHAN DRUG 771520
Created by admin on Mon Mar 31 17:35:03 GMT 2025 , Edited by admin on Mon Mar 31 17:35:03 GMT 2025
NCI_THESAURUS C1742
Created by admin on Mon Mar 31 17:35:03 GMT 2025 , Edited by admin on Mon Mar 31 17:35:03 GMT 2025
Code System Code Type Description
ECHA (EC/EINECS)
202-607-8
Created by admin on Mon Mar 31 17:35:03 GMT 2025 , Edited by admin on Mon Mar 31 17:35:03 GMT 2025
PRIMARY
ChEMBL
CHEMBL964
Created by admin on Mon Mar 31 17:35:03 GMT 2025 , Edited by admin on Mon Mar 31 17:35:03 GMT 2025
PRIMARY
CAS
97-77-8
Created by admin on Mon Mar 31 17:35:03 GMT 2025 , Edited by admin on Mon Mar 31 17:35:03 GMT 2025
PRIMARY
DRUG BANK
DB00822
Created by admin on Mon Mar 31 17:35:03 GMT 2025 , Edited by admin on Mon Mar 31 17:35:03 GMT 2025
PRIMARY
RS_ITEM_NUM
1224008
Created by admin on Mon Mar 31 17:35:03 GMT 2025 , Edited by admin on Mon Mar 31 17:35:03 GMT 2025
PRIMARY
DAILYMED
TR3MLJ1UAI
Created by admin on Mon Mar 31 17:35:03 GMT 2025 , Edited by admin on Mon Mar 31 17:35:03 GMT 2025
PRIMARY
MERCK INDEX
m4677
Created by admin on Mon Mar 31 17:35:03 GMT 2025 , Edited by admin on Mon Mar 31 17:35:03 GMT 2025
PRIMARY Merck Index
IUPHAR
7168
Created by admin on Mon Mar 31 17:35:03 GMT 2025 , Edited by admin on Mon Mar 31 17:35:03 GMT 2025
PRIMARY
WIKIPEDIA
DISULFIRAM
Created by admin on Mon Mar 31 17:35:03 GMT 2025 , Edited by admin on Mon Mar 31 17:35:03 GMT 2025
PRIMARY
INN
1781
Created by admin on Mon Mar 31 17:35:03 GMT 2025 , Edited by admin on Mon Mar 31 17:35:03 GMT 2025
PRIMARY
DRUG CENTRAL
928
Created by admin on Mon Mar 31 17:35:03 GMT 2025 , Edited by admin on Mon Mar 31 17:35:03 GMT 2025
PRIMARY
RXCUI
3554
Created by admin on Mon Mar 31 17:35:03 GMT 2025 , Edited by admin on Mon Mar 31 17:35:03 GMT 2025
PRIMARY RxNorm
EVMPD
SUB06326MIG
Created by admin on Mon Mar 31 17:35:03 GMT 2025 , Edited by admin on Mon Mar 31 17:35:03 GMT 2025
PRIMARY
CHEBI
4659
Created by admin on Mon Mar 31 17:35:03 GMT 2025 , Edited by admin on Mon Mar 31 17:35:03 GMT 2025
PRIMARY
NCI_THESAURUS
C447
Created by admin on Mon Mar 31 17:35:03 GMT 2025 , Edited by admin on Mon Mar 31 17:35:03 GMT 2025
PRIMARY
EPA CompTox
DTXSID1021322
Created by admin on Mon Mar 31 17:35:03 GMT 2025 , Edited by admin on Mon Mar 31 17:35:03 GMT 2025
PRIMARY
NSC
25953
Created by admin on Mon Mar 31 17:35:03 GMT 2025 , Edited by admin on Mon Mar 31 17:35:03 GMT 2025
PRIMARY
MESH
D004221
Created by admin on Mon Mar 31 17:35:03 GMT 2025 , Edited by admin on Mon Mar 31 17:35:03 GMT 2025
PRIMARY
FDA UNII
TR3MLJ1UAI
Created by admin on Mon Mar 31 17:35:03 GMT 2025 , Edited by admin on Mon Mar 31 17:35:03 GMT 2025
PRIMARY
ALANWOOD
disulfiram
Created by admin on Mon Mar 31 17:35:03 GMT 2025 , Edited by admin on Mon Mar 31 17:35:03 GMT 2025
PRIMARY
PUBCHEM
3117
Created by admin on Mon Mar 31 17:35:03 GMT 2025 , Edited by admin on Mon Mar 31 17:35:03 GMT 2025
PRIMARY
HSDB
3317
Created by admin on Mon Mar 31 17:35:03 GMT 2025 , Edited by admin on Mon Mar 31 17:35:03 GMT 2025
PRIMARY
SMS_ID
100000081855
Created by admin on Mon Mar 31 17:35:03 GMT 2025 , Edited by admin on Mon Mar 31 17:35:03 GMT 2025
PRIMARY
Related Record Type Details
METABOLITE ACTIVE -> PRODRUG
METABOLITE -> PARENT
METABOLITE -> PARENT
METABOLITE -> PARENT
Related Record Type Details
ACTIVE MOIETY